Digital Pathology Business Plan for Both Clinical and ROI Success

By Kristin Althea O’Connor | From the Volume XXX, No. 9 – June 19, 2023 Issue

CEO SUMMARY: More pathology groups are ready to consider adopting whole-slide imaging and digital pathology. The decision to proceed should only be made after identifying the clinica…

Read More

---

Artificial Intelligence ‘Invades’ Pathology, Billing

By R. Lewis Dark | From the Volume XXIX, No. 3 – February 22, 2022 Issue

Predictions about the potential of artificial intelligence (AI) to transform nearly every area of healthcare are about to become reality. For the profession of laboratory medicine, AI is making speedy inroads into two areas. The first is anato…

Read More

---

First Digital Path AI Tool Cleared for Market by FDA

By Robert Michel | From the Volume XXVIII, No. 13 – September 27, 2021 Issue

CEO SUMMARY: In a first for the anatomic pathology profession, the Food and Drug Administration (FDA) has cleared for market a digital pathology image analysis product intended to aid pathologists in the diagnosis of prostate cancer. Developed by New York City-based Paige, the Paige…

Read More

---

Digital Pathology Image Service Delivers AI via the Internet

By Robert Michel | From the Volume XXVIII, No. 13 – September 27, 2021 Issue

IN GERMANY, AN EMERGING DIGITAL PATHOLOGY (DP) COMPANY has introduced a novel feature that could be a low-cost way for pathology groups to access artificial intelligence (AI) for digital image analysis. This would appeal to pathologists who may be reluctant to invest the substantial cost and time req…

Read More

---

Pathology Groups Should Plan to Use Digital Pathology

By Pamela Scherer McLeod

WHEN AN ANATOMIC PATHOLOGY GROUP CONSIDERS IMPLEMENTING digital pathology and whole-slide imaging (WSI) for primary diagnosis, it must identify and understand a range of challenges and opportunities. “Every pathology group should start by considering how it will use the related technologies of a…

Read More

---

Expert Sees Pros, Cons In DP and WSI Systems

By Joseph Burns | From the Volume XXVI No. 13 – September 23, 2019 Issue

CEO SUMMARY: Now that the FDA has cleared two digital pathology systems for use in primary diagnosis, a growing number of pathology groups are taking up the question of whether and when they should adopt and use a digital pathology system and whole slide imaging. One pathologist with hand…

Read More

---

Outside US, Digital Path Moves Ahead Rapidly

By Joseph Burns | From the Volume XXVI No. 10 – July 22, 2019 Issue

CEO SUMMARY: Implementation of digital pathology and whole-slide imaging systems in the United States lags behind that of other countries for two reasons. One is a more acute shortage of pathologists in those countries and the other is a less restrictive regulatory environment. In some lo…

Read More

---

FDA Clears Aperio’s Digital Pathology System

By Joseph Burns | From the Volume XXVI No. 10 – July 22, 2019 Issue

CEO SUMMARY: In May, the FDA announced clearance for Leica Biosystems to market its Aperio AT2 DX System for clinical diagnosis in the United States. The Aperio AT2 DX System is intended for in vitro diagnostic use as an aid to pathologists reviewing and interpreting digital images of sur…

Read More

---

For Top 20 Tests, CMS to Cut Payment by 28% in 2018-2020

By Robert Michel | From the Volume XXIV No. 14 – October 9, 2017 Issue

ON SEPT. 22, MEDICARE OFFICIALS RELEASED THE DRAFT PRICES for the 2018 Clinical Laboratory Fee Schedule. The bad news for the lab industry is that the fee cuts are deeper than the federal Centers for Medicare and Medicaid Services had predicted earlier. The price cuts to clinical la…

Read More

---

Digital Pathology Systems Will Create Opportunities

By R. Lewis Dark | From the Volume XXIV No. 7 – May 15, 2017 Issue

CEO SUMMARY: Advanced Pathology Associates, a 15-member private pathology group practice, had the distinction of generating data for the clinical study that Philips submitted to the Food and Drug Administra…

Read More

---